Navamedic ASA

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 10 November 2008) The Board of Directors of Navamedic ASA has decided to focus the company's further development on its Direct Sales and Marketing business, through the subsidiary Vitaflo Scandinavia AB. The company will initiate a process to move the main management functions currently conducted at the Navamedic office in Oslo to Gothenburg. As the Glucomed product is no longer a core asset, the product may be sold off given a fair price and under the right conditions.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 27 October, 2008) Board member Roland Sandstrøm has decided to resign from the Board of Directors in Navamedic ASA due to heavy workload. Roland Sandstrøm will continue his work for Navamedic as Executive Chairman of the Board in the subsidiary Vitaflo Scandinavia AB.

Navamedic ASA (OSL:NAVA) Please find attached the third quarter report 2008 for Navamedic ASA.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 20 October, 2008) Navamedic ASA invites to a presentation of the company's Q3 2008 results on 22 October 2008. The presentation will take place at Felix Conference Centre at Aker Brygge, Bryggetorget 3, 0114 Oslo, and will start at 08:00.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 2 October 2008) Navamedic ASA terminates the market maker agreement with Handelsbanken with effect from 2 December 2008.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 26 September 2008) Navamedic ASA has been informed that the preliminary position of the transparency committee in France is to de-reimburse all symptomatic slow acting drugs in osteoarthritis (SYSADOA).

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 22 September 2008) Navamedic ASA has signed a marketing and distribution agreement with Queisser Pharma for Glucomed in Germany. Navamedic will from 2009 have two partners to market Glucomed in the German market.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 9 September 2008). Please find attached today's presentation given at DnB NOR Health Care Summit in Oslo.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 4 September 2008). A new study performed at Karolinska Institutet, Stockholm, demonstrates the efficacy of Naltrexone for the treatment of amphetamine dependence. Naltrexon Vitaflo, marketed by Navamedic's subsidiary Vitaflo Scandinavia, is the only naltrexone product in Sweden and Denmark.

Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 13 August 2008) Primary insider and CEO, Øyvind W. Brekke, has today acquired 16,000 shares in Navamedic ASA at an average price of 8.13 per share through his private company Advance Invest & Consulting AS. Advance Invest & Consulting AS (Øyvind W. Brekke) has a new holding in Navamedic ASA after this transaction of 428,060 shares.